Litcius/Paper detail

Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases

Dhruv Ahuja, Kuan-Hung Yeh, Sagar Patel, Han Hee Lee, Shane W. Goodwin, Virginia Solitano, Christopher Ma, Ashwin N. Ananthakrishnan, Namrata Singh, Vipul Jairath, Ronghui Xu, Siddharth Singh

2025Clinical Gastroenterology and Hepatology12 citationsDOI

Topics & Concepts

MedicineInternal medicineConcomitantInflammatory bowel diseaseMaceJanus kinaseGastroenterologyProportional hazards modelHazard ratioUlcerative colitisDiseaseConfidence intervalCytokineConventional PCIMyocardial infarctionInflammatory Bowel DiseaseRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and Treatments
Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases | Litcius